U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07486843) titled 'Preventing Structural Damage in Early Psoriatic Arthritis' on Jan. 23.
Brief Summary: Investigators hypothesize that TNFi is superior to SC MTX in preventing structural damage in early, treatment-naive PsA, assessed using HR-pQCT. The study aims to ascertain:
- The effect of SC MTX and TNFi (adalimumab biosimilar) on erosion and enthesiophyte progression in early PsA by HR-pQCT.
Participants will be:
* Randomized in a 1:1 ratio to either the SC MTX group or the TNFi group.
* HR-pQCT of MCPJ 2-4 will be performed at baseline, week 24, and one year.
The primary outcome is the comparison of change in erosion volume over MCPJ 2-4 ...